<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35187661</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0404</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Acta neurologica Scandinavica</Title><ISOAbbreviation>Acta Neurol Scand</ISOAbbreviation></Journal><ArticleTitle>Natural history and remarkable psychiatric state of late-onset amyotrophic lateral sclerosis in China.</ArticleTitle><Pagination><StartPage>24</StartPage><EndPage>33</EndPage><MedlinePgn>24-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ane.13598</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting motor neurons. The proportion of late-onset ALS in China were low and may have distinct clinical and genetic manifestations. We aimed to investigate the natural history and remarkable psychiatric state of ALS with age at onset over 60&#xa0;years in China.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">We collected all ALS cases from 2017 to 2020 in our center and focused on late-onset ALS patients particularly, by analyzing the clinical data, including the ALS onset and disease progression. Anxiety, depression, cognitive function, and sleep quality were assessed to reflect the psychiatric state.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 193&#xa0;late-onset ALS patients were included in this study. The median age at onset of late-onset ALS was 65&#xa0;years with the quartile from 62 to 68&#xa0;years. When compared with 446 non-late-onset ALS, late-onset ALS showed distinct clinical presentation, with lower ALS Functional Rating Scale-Revised at diagnosis and faster rate of progression. Remarkably, late-onset ALS were suffering from worse psychiatric state, including serious anxiety and depression, as well as worse cognitive function with sleep quality. The abnormal psychiatric state was more pronounced in female patients of late-onset.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In the current study, ALS patients with late-onset showed unique clinical features. Severe psychiatric conditions and faster progression in the early stage of the disease of late-onset ALS indicated the need for more social and psychiatric support in this population.</AbstractText><CopyrightInformation>&#xa9; 2022 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sen</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1131-5222</Identifier><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Minying</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jianing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Pian</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Weineng</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Ruojie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xiaoli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2017YFC0907703</GrantID><Agency>National Key Research and Development Program of China</Agency><Country/></Grant><Grant><GrantID>82001332</GrantID><Agency>Young Scientist Fund of the National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2020B1212060017</GrantID><Agency>Diagnosis and Treatment of Major Neurological Diseases</Agency><Country/></Grant><Grant><GrantID>2020B1111170002</GrantID><Agency>Guangdong Provincial Clinical Research Center for Neurological Diseases</Agency><Country/></Grant><Grant><GrantID>2015B050501003</GrantID><Agency>Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases</Agency><Country/></Grant><Grant><GrantID>2020A0505020004</GrantID><Agency>Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Neurol Scand</MedlineTA><NlmUniqueID>0370336</NlmUniqueID><ISSNLinking>0001-6314</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">China</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical features</Keyword><Keyword MajorTopicYN="N">late-onset</Keyword><Keyword MajorTopicYN="N">psychiatric state</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35187661</ArticleId><ArticleId IdType="doi">10.1111/ane.13598</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084-2098.</Citation></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172.</Citation></Reference><Reference><Citation>Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol. 2017;13(2):96-104.</Citation></Reference><Reference><Citation>Huisman MH, de Jong SW, van Doormaal PT, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82(10):1165-1170.</Citation></Reference><Reference><Citation>Liu MS, Cui LY, Fan DS. Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand. 2014;129(3):163-167.</Citation></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81(4):385-390.</Citation></Reference><Reference><Citation>Turner MR, Barnwell J, Al-Chalabi A, Eisen A. Young-onset amyotrophic lateral sclerosis: historical and other observations. Brain. 2012;135(Pt 9):2883-2891.</Citation></Reference><Reference><Citation>Sabatelli M, Madia F, Conte A, et al. Natural history of young-adult amyotrophic lateral sclerosis. Neurology. 2008;71(12):876-881.</Citation></Reference><Reference><Citation>Santos MO, Gromicho M, Pinto S, de Carvalho M. Very late-onset amyotrophic lateral sclerosis in a Portuguese cohort. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2018;19(7-8):619-622.</Citation></Reference><Reference><Citation>Dandaba M, Couratier P, Labrunie A, et al. Characteristics and prognosis of oldest old subjects with amyotrophic lateral sclerosis. Neuroepidemiology. 2017;49(1-2):64-73.</Citation></Reference><Reference><Citation>Aragones JM, Altimiras J, Roura-Poch P, et al. Amyotrophic lateral sclerosis: A higher than expected incidence in people over 80 years of age. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(7-8):522-527.</Citation></Reference><Reference><Citation>Palese F, Sartori A, Logroscino G, Pisa FE. Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):176-185.</Citation></Reference><Reference><Citation>Atsuta N, Watanabe H, Ito M, et al. Age at onset influences on wide-ranged clinical features of sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2009;276(1-2):163-169.</Citation></Reference><Reference><Citation>Forbes RB, Colville S, Swingler RJ, Scottish ALSMNDR. The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over. Age Ageing. 2004;33(2):131-134.</Citation></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-292.</Citation></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265-267.</Citation></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628-632.</Citation></Reference><Reference><Citation>Moberg PJ, Lazarus LW, Mesholam RI, et al. Comparison of the standard and structured interview guide for the Hamilton Depression Rating Scale in depressed geriatric inpatients. Am J Geriatr Psychiatry. 2001;9(1):35-40.</Citation></Reference><Reference><Citation>Wang XDWX. Ma H. Mental Health Journal Press; 1999.</Citation></Reference><Reference><Citation>Wei Q, Zheng Z, Guo X, et al. Association between depression and survival in Chinese amyotrophic lateral sclerosis patients. Neurol Sci. 2016;37(4):557-563.</Citation></Reference><Reference><Citation>Zhang Y, Cao Y, Wang L. The effects of a new, improved Chinese medicine, Gengnianchun formula granules, on hot flushes, depression, anxiety, and sleep in Chinese peri- and postmenopausal women: a randomized placebo-controlled trial. Menopause. 2020;27(8):899-905.</Citation></Reference><Reference><Citation>Yokoi D, Atsuta N, Watanabe H, et al. Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis. J Neurol. 2016;263(6):1129-1136.</Citation></Reference><Reference><Citation>Armon C, Kurland LT, Daube JR, O'Brien PC. Epidemiologic correlates of sporadic amyotrophic lateral sclerosis. Neurology. 1991;41(7):1077-1084.</Citation></Reference><Reference><Citation>Lin J, Chen W, Huang P, Xie Y, Zheng M, Yao X. The distinct manifestation of young-onset amyotrophic lateral sclerosis in China. Amyotroph Lateral Scler Frontotemporal Degener. 2020;22:1-8.</Citation></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, et al. Clinical features of amyotrophic lateral sclerosis in south-west China. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):512-519.</Citation></Reference><Reference><Citation>Shetty AK, Upadhya R, Madhu LN, Kodali M. Novel insights on systemic and brain aging, stroke, amyotrophic lateral sclerosis, and Alzheimer's disease. Aging Dis. 2019;10(2):470-482.</Citation></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G, group Ps. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740-746.</Citation></Reference><Reference><Citation>Kano O, Iwamoto K, Ito H, et al. Limb-onset amyotrophic lateral sclerosis patients visiting orthopedist show a longer time-to-diagnosis since symptom onset. BMC Neurol. 2013;13:19.</Citation></Reference><Reference><Citation>Cui F, Zhu W, Zhou Z, et al. Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease. Neuropsychiatr Dis Treat. 2015;11:2847-2854.</Citation></Reference><Reference><Citation>Barc K, Szacka K, Nieporecki K, et al. Emotional lability at disease onset is an independent prognostic factor of faster disease progression in amyotrophic lateral sclerosis. Aging Dis. 2020;11(5):1021-1028.</Citation></Reference><Reference><Citation>Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys&#x2019; estimates. Arch Gen Psychiatry. 2002;59(2):115-123.</Citation></Reference><Reference><Citation>Roos E, Mariosa D, Ingre C, et al. Depression in amyotrophic lateral sclerosis. Neurology. 2016;86(24):2271-2277.</Citation></Reference><Reference><Citation>Chen W, Xie Y, Zheng M, et al. Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China. Eur J Neurol. 2020;27(6):1017-1022.</Citation></Reference><Reference><Citation>Chen D, Guo X, Zheng Z, et al. Depression and anxiety in amyotrophic lateral sclerosis: correlations between the distress of patients and caregivers. Muscle Nerve. 2015;51(3):353-357.</Citation></Reference><Reference><Citation>Liu L, Gou Z, Zuo J. Social support mediates loneliness and depression in elderly people. J Health Psychol. 2016;21(5):750-758.</Citation></Reference><Reference><Citation>Korner S, Kollewe K, Ilsemann J, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20(4):647-654.</Citation></Reference><Reference><Citation>Ohta Y, Sato K, Takemoto M, et al. Behavioral and affective features of amyotrophic lateral sclerosis patients. J Neurol Sci. 2017;381:119-125.</Citation></Reference><Reference><Citation>Bersano E, Sarnelli MF, Solara V, et al. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(5-6):373-379.</Citation></Reference><Reference><Citation>Yuan Q, Jia J. Reduced cognitive function in Chinese patients with early amyotrophic lateral sclerosis and associated factors. Int J Neurosci. 2010;120(10):641-646.</Citation></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, et al. Screening for cognitive impairment in a Chinese ALS population. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):40-45.</Citation></Reference><Reference><Citation>Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: current perspectives. Nat Sci Sleep. 2019;11:97-111.</Citation></Reference><Reference><Citation>Diaz-Abad M, Buczyner JR, Venza BR, et al. Poor sleep quality in patients with amyotrophic lateral sclerosis at the time of diagnosis. J Clin Neuromuscul Dis. 2018;20(2):60-68.</Citation></Reference><Reference><Citation>Panda S, Gourie-Devi M, Sharma A. Sleep disorders in amyotrophic lateral sclerosis: a questionnaire-based study from India. Neurol India. 2018;66(3):700-708.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>